BMS signs fibrosis deal with Danish biotech company

A Danish biotech company is now going to develop biomarkers for US-based drug group Bristol-Myers Squibb to potentially aid in diagnosing and monitoring fibrotic diseases, including fatty liver disease NASH.

Photo: /Ritzau/AP/Mel Evans/

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles